Samsung Bioepis Co., Ltd. announced today that the company has entered into an Asset Purchase Agreement (APA) with Biogen regarding Samsung Bioepis’ two ophthalmology assets: BYOOVIZ ® (ranibizumab), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback